[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Fakultas Kedokteran Universitas Indonesia\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":137},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,77,109],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100629169","phase-4-mycological-efficacy-and-safety-of-ketoconazole-2-shampoo-with-a-seven-day-versus-three-day-treatment-duration-in-pityriasis-versicolor-100629169",false,"NCT07471178","Mycological Efficacy and Safety of Ketoconazole 2% Shampoo With a Seven-Day Versus Three-Day Treatment Duration in Pityriasis Versicolor","Mycological Efficacy and Safety of Ketoconazole 2% Shampoo With a Seven-Day Versus Three-Day Treatment Duration in Pityriasis Versicolor: A Double-Blind Randomized Clinical Trial","Inclusion Criteria:\n\n* Male and female patients aged 12 years or older\n* Patients with pityriasis versicolor confirmed mycologically by the presence of short hyphae and round spores on direct microscopic examination using potassium hydroxide (KOH) preparation and Parker Blue-Black® ink\n* Patients who are willing to participate in the study and provide written informed consent after receiving adequate explanation of the study; informed assent is obtained for participants younger than 18 years\n* Participants younger than 18 years who have written permission from a parent or legal guardian\n\nExclusion Criteria:\n\n* Patients in an immobilized condition\n* Patients with pityriasis versicolor lesions limited exclusively to the face, without involvement of other body areas\n* History of hypersensitivity to ketoconazole\n* Use of systemic antifungal agents or systemic corticosteroids within one month prior to study enrollment\n* Use of topical antifungal agents or topical corticosteroids within two weeks prior to study enrollment\n* Patients with severe immunosuppression\n* Pregnant or breastfeeding women",true,"ALL","12 Years",{"count":20,"type":21},76,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The goal of this clinical study is to find out whether using ketoconazole 2% shampoo for seven days works better than using it for three days in treating pityriasis versicolor. The study will also evaluate the safety of both treatment durations.\n\nThe main questions this study aims to answer are:\n\n* Does treatment with ketoconazole 2% shampoo for seven days result in better mycological efficacy compared with three days of treatment in patients with pityriasis versicolor?\n* Does treatment with ketoconazole 2% shampoo for seven days lead to better clinical improvement compared with three days of treatment?\n* Are there differences in side effects between the seven-day and three-day ketoconazole 2% shampoo treatment regimens?\n* Are there differences in dermoscopic features of pityriasis versicolor before and after treatment with ketoconazole 2% shampoo when used for seven days compared with three days?",[27],"Pityriasis Versicolor",[27,29,30],"Ketoconazole","Mycological Cure","NOT_YET_RECRUITING","2026-03-11",{"date":34,"type":35},"2026-03-13","ACTUAL",{"date":37,"type":21},"2026-02",{"date":39,"type":21},"2026-06",{"name":41,"class":42},"Fakultas Kedokteran Universitas Indonesia","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":50,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":64,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},"100616643","longitudinal-evaluation-of-direct-neurotization-technique-in-breast-reconstruction-with-fully-autologous-components-100616643","NCT07308275","Longitudinal Evaluation of Direct Neurotization Technique in Breast Reconstruction With Fully Autologous Components","Longitudinal Evaluation of Direct Neurotization Technique in Breast Reconstruction With Fully Autologous Components: An Assessment of BREAST-Q Sensation Module, Cutaneous Pressure Threshold, Neuregulin 1 (NRG1) Expression, Nerve Fiber Cross-sectional Area, Intraepidermal Nerve Fiber Density (IENFD), and Breast Morphometry","Inclusion Criteria:\n\n* Female patients aged ≥18 years.\n* Patients with unilateral breast cancer who have undergone or will undergo unilateral mastectomy.\n* Patients undergoing breast reconstruction.\n* Patients with unilateral breast cancer regardless of adjuvant therapy status (receiving radiotherapy and\u002For chemotherapy or receiving no adjuvant therapy).\n* Willing to comply with all scheduled examinations and tissue sampling procedures.\n* Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n* History of peripheral neuropathy (e.g., diabetes mellitus with neuropathic complications).\n* Bilateral mastectomy.\n* Presence of skin or soft-tissue conditions of the breast that may interfere with sensory assessment.\n* Active smokers (use of tobacco, vape, or other nicotine products within 14 days prior to neurotization).\n* Refusal or inability to attend follow-up evaluations.","FEMALE","18 Years",{"count":53,"type":21},28,[55],"NA","This clinical trial aims to evaluate whether direct neurotization using fully autologous components during autologous breast reconstruction improves postoperative breast sensation and sensory-related quality of life in women undergoing unilateral mastectomy. Direct neurotization involves coapting the recipient intercostal nerve to an autologous nerve graft placed within the flap to facilitate reinnervation.\n\nThe study's primary questions are:\n\n1. Does direct neurotization using fully autologous nerve grafts improve cutaneous sensory recovery, as assessed by Semmes-Weinstein monofilament thresholds measured at standardized breast locations?\n2. Does neurotization enhance patient-reported sensory outcomes and quality of life, as assessed by the BREAST-Q Sensation Module?\n\nAs secondary objectives, the study will assess whether biological predictors of nerve regeneration correlate with sensory outcomes. These include:\n\n1. Neuregulin-1 (NRG1) expression in flap tissue biopsy;\n2. Cross-sectional area of the recipient nerve fibres;\n3. Breast morphometry measured at baseline and follow-up;\n4. Intraepidermal nerve fibre density (IENFD) on skin biopsy.\n\nParticipants will be randomly assigned to receive either:\n\n1. Neurotized autologous breast reconstruction using fully autologous graft components, or\n2. Standard (non-neurotized) autologous breast reconstruction.\n\nThe study will compare these groups to determine whether neurotization accelerates or enhances the return of breast sensation over a 6-month follow-up period, with evaluations at 1 month, 3 months, and 6 months after surgery.\n\nParticipants will undergo:\n\n1. Autologous breast reconstruction with or without direct neurotization as part of their planned cancer surgery.\n2. Sensory testing using Semmes-Weinstein monofilaments at baseline, 1, 3, and 6 months.\n3. Completion of BREAST-Q questionnaires evaluating breast sensation, symptoms, and quality of life at each follow-up visit.\n\n3\\. Intraoperative tissue sampling for NRG1 analysis and nerve morphometry. 4. Skin biopsy (if applicable) to assess intraepidermal nerve fibre density. 5. Breast morphometry assessment using a breast morphometry measurement software tool.\n\nThis study seeks to provide high-quality evidence on the effectiveness of direct neurotization using fully autologous components in restoring breast sensation and to explore biological predictors that may influence sensory recovery after autologous breast reconstruction.",[58,59,60,61,62,63],"Breast Reconstruction After Mastectomy","Neurotization","Mastectomy and Breast Reconstruction","Peripheral Nerve Regeneration","Sensory Function","Quality of Life (QOL)",[65,66,67,68],"breast neurotization","mastectomy","breast sensory","quality of life","2025-12-15",{"date":71,"type":35},"2025-12-29",{"date":69,"type":21},{"date":74,"type":21},"2027-04-15",{"name":41,"class":42},1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":89,"conditions":90,"keywords":96,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":4},"100604997","phase-2-n-acetylcysteine-roles-in-preserving-renal-function-measured-by-urinary-kim-1-kidney-injury-molecule-1-and-serum-creatinine-on-cancer-patients-with-cisplatin-based-chemotherapy-a-randomized-placebo-controlled-trial-100604997","NCT07156786","N-Acetylcysteine Roles in Preserving Renal Function Measured by Urinary KIM-1 (Kidney Injury Molecule-1) and Serum Creatinine on Cancer Patients With Cisplatin Based Chemotherapy: A Randomized Placebo-Controlled Trial","N-Acetylcysteine Role on Urinary KIM-1 and Serum Creatinine Level in Cancer Patient With Cisplatin Based Chemotherapy","Inclusion Criteria:\n\n* Patient with cancer\u002F malignancy proven by histopathological examination\n* Patient with GFR ≥60 ml\u002Fmins\u002F1,73 m²\n* Patient with normal complete blood count and liver function test result\n* Patient with good performance status (Karnofsky score ≥80)\n* Patients with cisplatin based chemotherapy\n\nExclusion Criteria:\n\n* Patient that can not tolerate N-Acetylcysteine usage\n* Patient with history of hypersensitivity to N-Acetylcysteine\n* Patient that given other potentially nephrotoxic drug, such as furosemide, non-steroidal anti-infammatory drugs, aminoglycosides, amphotericin B, cephalosporine\n* Patient that given other chemotherapy drug, such as permetrexed, ifosfamide, gemcitabin, bevacizumab, cetuxsimab\n* Patient with history of malignant or uncontrolled hypertension\n* patient with congestive heart failure, kidney structure abnormality, and acute infection\n* Pregnant or lactating women\n* Patient refusing to participate in the research",{"count":85,"type":21},72,[87,88],"PHASE2","PHASE3","The goal of this clinical trial is to learn if N-Acetylcysteine drug works to protect kidney function in adults patient with cancer. Kidney function will be measured by laboratory parameter using urine sample (KIM-1 urine) and blood sample (serum creatinine). The main questions it aims to answer are:\n\n1. Does N-Acetylcysteine lower the level of KIM-1 (Kidney Injury Molecule) in patients urine indicating kidney function protection?\n2. Does N-Acetylcysteine lower the level of creatinine in patients blood indicating kidney function protection?\n\nParticipants will:\n\n1. Had their blood and urine sample taken before taking the drugs (N-Acetylcysteine or placebo)\n2. Underwent cisplatin based chemotherapy\n3. Taken placebo or N-Acetylcysteine for seven days (1 day before chemotherapy, on the chemotherapy day, and 5 days after chemotherapy)\n4. Had their blood and urine sample taken twice after taking the drugs (1 week and 3 weeks after chemotherapy)\n5. Had their symptoms monitor during and after taking the drugs. Every possible side effect, hospitalization, or death will be recorded.",[91,92,93,94,95],"Kidney Function Issue","Acute Kidney Injury","Cancer (Solid Tumors)","Kidney Function Tests","Acetylcysteine Adverse Reaction",[97,98,99,100],"kidney injury molecule 1","KIM-1","Creatinine","N-Acetylcysteine","2025-09-13",{"date":103,"type":35},"2025-09-19",{"date":105,"type":21},"2025-09-15",{"date":107,"type":21},"2027-08-31",{"name":41,"class":42},{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":16,"sex":50,"minAge":116,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":22,"phases":120,"briefSummary":121,"conditions":122,"keywords":126,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":76},"100556197","effectiveness-of-cbt-in-improving-psycho-neuro-endocrine-factors-in-women-following-in-vitro-fertilization-program-100556197","NCT06521957","Effectiveness of CBT in Improving Psycho-Neuro-Endocrine Factors in Women Following In Vitro Fertilization Program","The Effectiveness of Cognitive Behavioral Therapy in Improving Psycho-Neuro-Endocrine Factors in Women Following In Vitro Fertilization Program","Inclusion Criteria:\n\n* Women with primary infertility\n* Aged 25-42 at the start of the study\n* Willing to participate in the study and willing to sign informed consent form\n* Minimum education of high school, able to read, write and understand Bahasa Indonesia\n\nExclusion Criteria:\n\n* Having one or multiple psychotic disorder(s)","25 Years","42 Years",{"count":119,"type":21},75,[55],"The goal of this clinical trial is to learn if Cognitive Behavioral Therapy (CBT) can improve psychological, neurological, and hormonal aspects in women undergoing In Vitro Fertilization (IVF). The main questions it aims to answer are:\n\n* Is CBT effective in improving psychological aspects (anxiety, depression, and coping mechanism) in women undergoing IVF?\n* Is CBT effective in improving neuroendocrine aspects (cortisol levels, neuroepinephrine levels, free trioodothyronine levels) in women underoing IVF?\n\nResearchers will compare CBT to no intervention to see if CBT is effective in improving psychoneuroendocrine aspects.",[123,124,125],"Cognitive Behavioral Therapy","Hormone Disturbance","In Vitro Fertilization",[123,127,125],"Psycho-Neuro-Endocrine","RECRUITING","2024-07-23",{"date":131,"type":35},"2024-07-26",{"date":133,"type":35},"2023-07-05",{"date":135,"type":21},"2025-06-01",{"name":41,"class":42},""]